CA2388974A1 - Medicament in order to induce tolerance - Google Patents

Medicament in order to induce tolerance Download PDF

Info

Publication number
CA2388974A1
CA2388974A1 CA002388974A CA2388974A CA2388974A1 CA 2388974 A1 CA2388974 A1 CA 2388974A1 CA 002388974 A CA002388974 A CA 002388974A CA 2388974 A CA2388974 A CA 2388974A CA 2388974 A1 CA2388974 A1 CA 2388974A1
Authority
CA
Canada
Prior art keywords
antigen
medicament
inhibitor
beta
tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388974A
Other languages
English (en)
French (fr)
Inventor
Thomas Wilckens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onepharm Research and Development GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388974A1 publication Critical patent/CA2388974A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
CA002388974A 1999-10-28 2000-10-27 Medicament in order to induce tolerance Abandoned CA2388974A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951970.6 1999-10-28
DE19951970A DE19951970A1 (de) 1999-10-28 1999-10-28 Arzneimittel für die Toleranzinduktion
PCT/EP2000/010594 WO2001030383A2 (de) 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion

Publications (1)

Publication Number Publication Date
CA2388974A1 true CA2388974A1 (en) 2001-05-03

Family

ID=7927188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388974A Abandoned CA2388974A1 (en) 1999-10-28 2000-10-27 Medicament in order to induce tolerance

Country Status (9)

Country Link
EP (1) EP1223974A2 (de)
JP (1) JP2003512438A (de)
KR (1) KR20020057986A (de)
CN (1) CN1391479A (de)
AU (1) AU784245B2 (de)
CA (1) CA2388974A1 (de)
DE (1) DE19951970A1 (de)
NZ (1) NZ518567A (de)
WO (1) WO2001030383A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
AU2004216559B2 (en) * 2003-02-28 2010-05-27 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
JP2007533625A (ja) * 2003-09-22 2007-11-22 バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性及び／又は免疫媒介性の骨量減少の予防及び治療
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
KR20230104990A (ko) 2011-04-29 2023-07-11 셀렉타 바이오사이언시즈, 인크. 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성합성 나노운반체
CA2910578C (en) 2013-05-03 2024-02-27 Selecta Biosciences, Inc. Local, concomitant administration of tolerogenic synthetic nanocarriers to reduce type i and type iv hypersensitivity
BR112017001601A2 (pt) 2014-09-07 2017-11-21 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência antiviral de modulação da expressão genética
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
GB8824835D0 (en) * 1988-10-24 1988-11-30 Univ Court Of The University O Administrations of corticosteroids
DK0494224T3 (da) * 1989-09-25 2000-08-07 Univ Utah Res Found Anvendelse af steroidhormoner i sammensætninger til induktion af T-cellelymfokinproduktion
JPH04243833A (ja) * 1991-01-28 1992-08-31 Tsumura & Co １１β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5883240A (en) * 1995-08-24 1999-03-16 Baker Medical Research Institute Genetic sequences encoding glucocorticoid dehydrogenases and uses therefor

Also Published As

Publication number Publication date
AU784245B2 (en) 2006-02-23
CN1391479A (zh) 2003-01-15
EP1223974A2 (de) 2002-07-24
AU1997201A (en) 2001-05-08
JP2003512438A (ja) 2003-04-02
WO2001030383A2 (de) 2001-05-03
WO2001030383A3 (de) 2001-11-08
KR20020057986A (ko) 2002-07-12
DE19951970A1 (de) 2001-05-03
NZ518567A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
AU784245B2 (en) Medicament in order to induce tolerance
Powrie et al. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ T cells.
EP3636666A1 (de) Neuartige immunogene peptide
EP2252329B1 (de) Beseitigung von immunreaktionen gegen virale vektoren
Herz et al. Animal models of type I allergy using recombinant allergens
US9358277B2 (en) DNA vaccines and methods for the prevention of transplantation rejection
CN101365494A (zh) 治疗自身免疫性疾病的组合物和方法
CN102762225B (zh) 用于针对桦树过敏的疫苗的肽
IL218269A (en) DNA vaccines encoded into heat-loss proteins
Horner et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity
WO1994023737A1 (en) Methods and compositions for delaying or preventing the onset of autoimmune disease
KR20100022022A (ko) 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
Dénes et al. Autoantigens plus interleukin-10 suppress diabetes autoimmunity
Ou et al. Intranasal immunization with DNA vaccine coexpressing Der p 1 and ubiquitin in an allergic rhinitis mouse model
EP1536826B1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
Dénes et al. Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses
Ferreira et al. Customized antigens for desensitizing allergic patients
Biregani et al. Allergen specific immunotherapy with plasmid DNA encoding OVA-immunodominant T cell epitope fused to Tregitope in a murine model of allergy
US20070274949A1 (en) Cd25 Dna Vaccines for Treating and Preventing T-Cell Mediated Diseases
AU2021267369A1 (en) Immunogenic peptides with extended oxidoreductase motifs
Verhagen et al. Advances in allergen-specific immunotherapy
Liu et al. Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial
Chan et al. Recombinant adenovirus encoding gp100 modulates experimental melanin-protein induced uveitis (EMIU)
Soyer et al. Immunologic Responses to Sublingual Allergen Immunotherapy
Caspi Immunotherapy of uveitis: is gene therapy in our future?

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead